167 related articles for article (PubMed ID: 24610041)
1. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.
Schirrmacher V
Cancer Immunol Immunother; 2014 Jun; 63(6):535-43. PubMed ID: 24610041
[TBL] [Abstract][Full Text] [Related]
2. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
[TBL] [Abstract][Full Text] [Related]
3. Effective immune rejection of advanced metastasized cancer.
Schirrmacher V; Beckhove P; Kruger A; Rocha M; Umansky V; Fichtner K; Hull W; Zangemeisterwittke U; Griesbach A; Jurianz K; Vonhoegen P
Int J Oncol; 1995 Mar; 6(3):505-21. PubMed ID: 21556565
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
[TBL] [Abstract][Full Text] [Related]
5. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
Zangemeister-Wittke U; Schirrmacher V
Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
[TBL] [Abstract][Full Text] [Related]
6. Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice.
Gresser I; Greco G; Santini SM; Woodrow D; Mecchia M; Parlato S; Logozzi M; Venditti M; Maunoury MT; Belardelli F
J Interferon Cytokine Res; 1998 Sep; 18(9):667-79. PubMed ID: 9781805
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.
Schirrmacher V; Müerköster S; Umansky V
Clin Cancer Res; 1998 Nov; 4(11):2635-45. PubMed ID: 9829726
[TBL] [Abstract][Full Text] [Related]
8. Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells.
Rocha M; Umansky V; Lee KH; Hacker HJ; Benner A; Schirrmacher V
Blood; 1997 Mar; 89(6):2189-202. PubMed ID: 9058744
[TBL] [Abstract][Full Text] [Related]
9. Tumor-immune memory T cells from the bone marrow exert GvL without GvH reactivity in advanced metastasized cancer.
Schirrmacher V; Beckhove P; Choi C; Griesbach A; Mahnke Y
Int J Oncol; 2005 Oct; 27(4):1141-9. PubMed ID: 16142333
[TBL] [Abstract][Full Text] [Related]
10. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
Kaido T; Maury C; Schirrmacher V; Gresser I
Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
[TBL] [Abstract][Full Text] [Related]
11. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
Cancer Immunol Immunother; 1990; 31(4):236-42. PubMed ID: 2379219
[TBL] [Abstract][Full Text] [Related]
12. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
13. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
15. Changes in liver glycogen and lipid metabolism during transient graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivity.
Lee K; Hacker H; Umansky V; Schirrmacher V; Rocha M
Int J Oncol; 1996 Oct; 9(4):635-43. PubMed ID: 21541563
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a murine lymphoma cell line by 31P-NMR spectroscopy: in vivo monitoring of the local anti-tumor effects of systemic immune cell transfer.
Fichtner KP; Schirrmacher V; Griesbach A; Hull WE
Int J Cancer; 1996 May; 66(4):484-95. PubMed ID: 8635864
[TBL] [Abstract][Full Text] [Related]
17. Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Marcus A; Waks T; Eshhar Z
Blood; 2011 Jul; 118(4):975-83. PubMed ID: 21653325
[TBL] [Abstract][Full Text] [Related]
18. The allogeneic response and tumor immunity.
Fabre JW
Nat Med; 2001 Jun; 7(6):649-52. PubMed ID: 11385492
[TBL] [Abstract][Full Text] [Related]
19. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice.
Aizawa S; Sado T
Transplantation; 1991 Nov; 52(5):885-9. PubMed ID: 1949175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
